Products
Platform
Research
Market
Learn
Compare Baroda BNP Paribas Health and Wellness Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.28 | 1.87 |
NAV | ₹9.74 | ₹40.33 |
Fund Started | 09 Jun 2025 | 25 Jun 2018 |
Fund Size | ₹614.49 Cr | ₹6226.82 Cr |
Exit Load | Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹500
₹100
Expense Ratio
2.28
1.87
NAV
₹9.74
₹40.33
Fund Started
09 Jun 2025
25 Jun 2018
Fund Size
₹614.49 Cr
₹6226.82 Cr
Exit Load
Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | - | 2.62% |
3 Year | - | 28.00% |
5 Year | - | 20.28% |
1 Year
-
2.62%
3 Year
-
28.00%
5 Year
-
20.28%
Holding Analysis
Equity | 94.77% | 97.55% |
Cash | -2.65% | 2.45% |
Equity
94.77%
97.55%
Cash
-2.65%
2.45%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.64% |
Divi's Laboratories Ltd. | 7.64% |
Mankind Pharma Ltd. | 7.53% |
Apollo Hospitals Enterprise Ltd. | 6.03% |
Cipla Ltd. | 5.44% |
Max Healthcare Institute Ltd. | 5.44% |
Abbott India Ltd. | 4.29% |
Aster DM Healthcare Ltd. | 4.08% |
Torrent Pharmaceuticals Ltd. | 3.81% |
Astrazeneca Pharma India Ltd. | 3.33% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.58% |
Dr. Reddy's Laboratories Ltd. | 9.10% |
Divi's Laboratories Ltd. | 8.75% |
Aurobindo Pharma Ltd. | 8.25% |
Cipla Ltd. | 6.92% |
Lupin Ltd. | 5.43% |
Alkem Laboratories Ltd. | 4.05% |
Biocon Ltd. | 3.11% |
Gland Pharma Ltd. | 2.97% |
Mankind Pharma Ltd. | 2.95% |
Fund Manager
Name | Sanjay Chawla | Dharmesh Kakkad |
Start Date | 09 Jun 2025 | 23 Feb 2021 |
Name
Sanjay Chawla
Dharmesh Kakkad
Start Date
09 Jun 2025
23 Feb 2021
About Fund
Description | The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 09 Jun 2025 | 25 Jun 2018 |
Description
The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
09 Jun 2025
25 Jun 2018